Armenia Medical Device Registration: Local Filing vs Recognizing State Filing Decision Tree

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Armenia offers two usable routes within the Union registration system: local filing as the reference state and follow-on filing as a recognizing state. The decision rule given by GRZAN is simple and turns on the number of final sales destinations: if the destination is Armenia alone, the follow-on route as a recognizing state is the safer choice; if the destinations include two or more member states, place Armenia in the recognizing position and the largest market country in the reference position. The direct cost of choosing the wrong route is having to resubmit the entire registration dossier under a second procedure.

2. Legal basis

RegulationDocument numberPublication date (effective date)Provisions
Rules for the Registration and Assessment of Medical Devices in Terms of Safety, Quality and EffectivenessDecision No. 46 of the Council of the Eurasian Economic Commission, 2016-02-12Amended by Council Decision No. 144 of 2021-12-24Article 16; Article 17; Article 18
Requirements for the Implementation, Maintenance and Assessment of Quality Management Systems for Medical Devices According to Potential Use RisksDecision No. 106 of the Council of the Eurasian Economic Commission, 2017-11-10Amended by Council Decision No. 43 of 2026-04-27 (effective 2026-06-18)Articles 30 to 35
Rules for the Classification of Medical Devices According to Potential Use RisksDecision No. 173 of the Board of the Eurasian Economic Commission, 2015-12-22Amended by No. 65 of 2023-05-23 and No. 18 of 2025-02-18Classification provisions

3. Expert insights

Insight 1: the workload under the two routes is distributed completely differently. Under the local filing route, the applicant submits the complete registration dossier to Armenia, the SCDMTE performs the assessment and organizes testing and production inspections, and the Ministry of Health issues the certificate. Under the follow-on route, the complete dossier is filed in another member state as the reference state, and Armenia only carries out the harmonization procedure on the expert opinion of that reference state. GRZAN points out that under the former the workload concentrates on the localization of documents into Russian and Armenian, while under the latter it concentrates on responsiveness during the harmonization period, so staffing plans should differ accordingly.

Insight 2: Article 18 determines what Armenia can see under the follow-on route. The provision states that, apart from the documents for use or operation of the medical device, the maintenance manual, labeling and packaging data, including full-color packaging and label artwork, and the label texts in Russian and in the national languages of the member states, the documents contained in the registration dossier are confidential information and are provided only to the interested authorized bodies, meaning expert organizations, of the member states. GRZAN points out that under the follow-on route the instructions for use and the label texts are the contents Armenia will inevitably review; both must be localized into Armenian and Russian before filing, otherwise a deficiency request during harmonization is practically guaranteed.

Insight 3: the territorial arrangement of production inspections is linked to the route choice. Under Articles 30 to 35 of Decision No. 106, production inspections are divided into initial, periodic, meaning planned, and unscheduled inspections; the initial production inspection is carried out within the Union registration procedure, the inspection report is valid for 3 years, and periodic planned production inspections take place every 3 years. GRZAN points out that under the follow-on route the initial inspection is still organized by the reference state and the inspection report is recognized across the Union, so the production inspection is not repeated because one additional recognizing state is added.

Insight 4: the six-step decision tree.

  1. Define the destinations: Armenia only, go to step 2; other countries included, go to step 3.
  2. Evaluate the local entity: is an Armenian authorized representative and mature Russian-language documentation already in place? If yes, choose local filing; if no, choose follow-on filing.
  3. Set the reference state: designate the member state with the largest expected sales volume as the reference state.
  4. List the recognizing states: include Armenia among the recognizing states and ensure at least one recognizing state is designated.
  5. Confirm testing and inspection capacity: verify that the reference state can organize technical tests, biological effect tests, clinical trials and production inspections for the product type.
  6. Keep a fallback option: predefine the handling when a recognizing state refuses harmonization, so the registration takes effect in the reference state only.

4. Practical recommendations

  1. Fix the route choice with the decision tree: embed the six-step decision tree into the project initiation template and retain the selection record with its rationale for every project, so that route decisions remain auditable over time.
  2. Localize the instructions even under the follow-on route: even when Armenia acts only as a recognizing state, the instructions for use and label texts will still be reviewed; prepare the Russian version in advance and the national language version as required.
  3. Do not repeat the production inspection: confirm that the inspection report issued by the reference state is recognized in Armenia, and avoid scheduling a duplicate inspection merely because Armenia joined as a recognizing state.
  4. Allow buffer for the harmonization period: the official position is that recognizing states harmonize for up to 30 working days, but the period for responding to deficiency requests is not counted within it, so additional time should be reserved in the plan (a practical estimate).

5. Verification checklist

  1. □ The route selection has been completed with the six-step decision tree and the record is retained.
  2. □ The combination of reference state and recognizing states has been confirmed, with at least one recognizing state.
  3. □ The role of Armenia, reference state or recognizing state, and the corresponding workload allocation have been confirmed.
  4. □ Russian-language instructions for use and label texts have been prepared.
  5. □ Recognition of the production inspection report in Armenia has been confirmed, with no duplicate inspection scheduled.
  6. □ The dossier documents that constitute confidential information under Article 18 have been identified.
  7. □ A fallback plan for the case where a recognizing state refuses harmonization has been drawn up.

Regulatory information verified as of October 30, 2026.

GRZAN service note. GRZAN assists medical device manufacturers with route selection between local filing and follow-on filing in the Eurasian Economic Union and Armenia, including decision-tree workshops, Russian and Armenian document localization, harmonization-period response management and inspection planning. Regulatory monitoring is updated continuously and confirmed against the official sources cited above. For inquiries, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail